Compare TALO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TALO | STOK |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | TALO | STOK |
|---|---|---|
| Price | $11.02 | $32.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $14.30 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $1,872,554,000.00 | $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $46.53 |
| Revenue Growth | 0.06 | ★ 1128.17 |
| 52 Week Low | $6.23 | $5.35 |
| 52 Week High | $12.20 | $38.69 |
| Indicator | TALO | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 53.64 |
| Support Level | $10.64 | $31.50 |
| Resistance Level | $11.39 | $33.90 |
| Average True Range (ATR) | 0.37 | 2.25 |
| MACD | -0.11 | -0.15 |
| Stochastic Oscillator | 24.44 | 38.02 |
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.